Skip to content

Effect of Self-acupressure on Middle Ear Barotrauma Associated With Hyperbaric Oxygen Therapy

Effect of Self-acupressure on Middle Ear Barotrauma Associated With Hyperbaric Oxygen Therapy: a Nonrandomized Clinical Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04311437
Enrollment
152
Registered
2020-03-17
Start date
2020-03-01
Completion date
2023-02-28
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperbaric Oxygen Therapy, Middle Ear Barotrauma

Keywords

Hyperbaric oxygen therapy, Middle ear barotrauma, Acupressure

Brief summary

Middle ear barotrauma (MEB) is the most common complication during hyperbaric oxygen therapy (HBOT). Though Valsalva and Toynbee maneuvers have been proposed to prevent MEB, still some patients discontinue HBOT due to severe otalgia, hemorrhage or perforation of tympanic membrane associated with HBOT. Currently, there is no optimal prophylactic management for MEB associated with HBOT. The aim of this protocol is to investigate the efficacy of self-acupressure therapy on MEB associated with HBOT.

Interventions

PROCEDURESelf-acupressure therapy

The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.

PROCEDURECombined Valsalva and Toynbee maneuvers

Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

This is a prospective nonrandomized controlled study. The participants will be assigned to two groups in a 1:1 ratio. The participants in the control group will receive conventional Valsalva and Toynbee maneuvers, while those in the experimental group will be given additional self-acupressure therapy.

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 20 years or order receiving the first HBOT * Alert consciousness

Exclusion criteria

* Pregnancy * Having any acute disorder of the ears or upper respiratory tract * Having evidence of neurologic dysfunction precluding them from making an informed decision * Having a tracheostomy or endotracheal intubation * Having received a myringotomy, tympanoplasty, mastoidectomy or tympanostomy tube placement.

Design outcomes

Primary

MeasureTime frameDescription
Modified Teed Classification1 monthThe Modified Teed Classification, with grades from 0 to 5: Grade 0 indicates symptoms with no ontological signs of trauma; Grade 1 indicates injection of the tympanic membrane; Grade 2 indicates Grade 1 plus injection plus mild hemorrhage within the tympanic membrane; Grade 3 indicates gross hemorrhage within the tympanic membrane; Grade 4 indicates free blood in the middle ear as evidenced by blueness and bulging; and Grade 5 indicates perforation of the tympanic membrane.

Secondary

MeasureTime frameDescription
Symptoms of MEB1 monthRecord the symptoms of MEB including feeling pressure in the ears, ear pain, headache, dizziness, vertigo, tinnitus and hearing loss. Each symptom is estimated using a 10-cm visual analogue scale with anchor points of 0 (no discomfort) and 10 (maximum discomfort).
Overall ear discomfort levels1 monthEstimated using a 10-cm visual analogue scale with anchor points of 0 (no discomfort) and 10 (maximum discomfort).

Countries

Taiwan

Contacts

PRINCIPAL_INVESTIGATORChun-Ting Liu, MD

Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026